<SEC-DOCUMENT>0001437749-22-000309.txt : 20220104
<SEC-HEADER>0001437749-22-000309.hdr.sgml : 20220104
<ACCEPTANCE-DATETIME>20220104171445
ACCESSION NUMBER:		0001437749-22-000309
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220104
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220104
DATE AS OF CHANGE:		20220104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39563
		FILM NUMBER:		22507396

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			GA
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			GA
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>govx20220103_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:govx="http://www.govx.com/20220104"><head>
	<title>govx20220103_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 1/3/2022 9:42:11 PM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20228K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20228K" name="dei:EntityCentralIndexKey">0000832489</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="govx-20220104.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20228K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-01-04</xbrli:startDate>
<xbrli:endDate>2022-01-04</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="d20228K_StatementClassOfStockAxis_CommonStock">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:CommonStockCustomMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-01-04</xbrli:startDate>
<xbrli:endDate>2022-01-04</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="d20228K_StatementClassOfStockAxis_WarrantsToPurchaseCommonStock">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:WarrantsToPurchaseCommonStockCustomMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-01-04</xbrli:startDate>
<xbrli:endDate>2022-01-04</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>WASHINGTON, D.C. 20549</b>&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&#xa0;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>FORM <ix:nonNumeric contextRef="d20228K" name="dei:DocumentType"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Pursuant to Section 13 or 15(d) of the</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Securities Exchange Act of 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Date of report (Date of earliest event reported):</b>&#xa0;&#xa0;<ix:nonNumeric contextRef="d20228K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><b>January 4, 2022</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&#xa0;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityRegistrantName"><b>GEOVAX LABS, INC.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>(Exact name of registrant as specified in its charter)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:14.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
			<td style="vertical-align:top;width:14.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityFileNumber"><b>001-39563</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
			<td style="vertical-align:top;width:14.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityTaxIdentificationNumber"><b>87-0455038</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:14.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(State or other jurisdiction of</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>incorporation or organization)</b></div>
			</td>
			<td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
			<td style="vertical-align:top;width:14.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Commission File No.)</b></div>
			</td>
			<td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
			<td style="vertical-align:top;width:14.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(IRS Employee Identification No.)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressAddressLine1"><b>1900 Lake Park Drive, Suite 380</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressCityOrTown"><b>Smyrna</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20228K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince"><b>Georgia</b></ix:nonNumeric> <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressPostalZipCode"><b>30080</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>(Address of principal executive offices) (Zip code)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>(<ix:nonNumeric contextRef="d20228K" name="dei:CityAreaCode"><b>678</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20228K" name="dei:LocalPhoneNumber"><b>384-7220</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>(Registrant</b>&#8217;<b>s telephone number, including area code)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13(e)-4(c))</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 18.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Title of each class</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 8.2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Trading</div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Symbol(s)</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 18.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Name of each exchange on which registered</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 18.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20228K_StatementClassOfStockAxis_CommonStock" name="dei:Security12bTitle">Common Stock</ix:nonNumeric>, par value $0.001 per share</div>
			</td>
			<td style="vertical-align: middle; width: 8.2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20228K_StatementClassOfStockAxis_CommonStock" name="dei:TradingSymbol">GOVX</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: middle; width: 18.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">The <ix:nonNumeric contextRef="d20228K_StatementClassOfStockAxis_CommonStock" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 18.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20228K_StatementClassOfStockAxis_WarrantsToPurchaseCommonStock" name="dei:Security12bTitle">Warrants to Purchase Common Stock</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: middle; width: 8.2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20228K_StatementClassOfStockAxis_WarrantsToPurchaseCommonStock" name="dei:TradingSymbol">GOVXW</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: middle; width: 18.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">The <ix:nonNumeric contextRef="d20228K_StatementClassOfStockAxis_WarrantsToPurchaseCommonStock" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Emerging growth company <ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial reporting standards provided pursuant to Section&#xa0;13(a) of the Exchange Act. &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 7.01 </b></div>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Regulation FD Disclosure.</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On January 4, 2022, GeoVax Labs, Inc. (&#8220;GeoVax&#8221; or the &#8220;Company&#8221;) issued a press release announcing the release of a shareholder update letter. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Forward-Looking Statements</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">This Current Report on Form 8-K and other reports filed by the Company from time to time with the Securities and Exchange Commission (collectively the &#8220;Filings&#8221;) contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company&#8217;s management as well as estimates and assumptions made by the Company&#8217;s management. When used in the Filings the words &#8220;believe,&#8221; &#8220;look forward to,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;is likely,&#8221; &#8220;will,&#8221; &#8220;expect&#8221; or the negative of these terms and similar expressions as they relate to the Company or the Company&#8217;s management identify forward looking statements.&#xa0;&#xa0;Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Company&#8217;s industry, operations and results of operations and any businesses that may be acquired by the Company. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Except as required by law, the Company does not undertake to update its forward-looking statements.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9.01 </b></div>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Financial Statements and Exhibits.</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(d)&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;Exhibits</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><span style="text-decoration: underline;">&#xa0;Exhibit No.</span></div>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline;">Description</span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">99.1</div>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_321172.htm" style="-sec-extract:exhibit;">Press release dated January 4, 2022</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">104</div>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SIGNATURE</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: January 4, 2022</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 50%;">&#xa0;</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GEOVAX LABS, INC.</div>
			</td>
			<td style="vertical-align: top; width: 12%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#xa0;</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">&#xa0;</td>
			<td style="vertical-align: top; width: 12%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#xa0;</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">&#xa0;</td>
			<td style="vertical-align: top; width: 12%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#xa0;</td>
			<td style="vertical-align: top; width: 3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Mark W. Reynolds</div>
			</td>
			<td style="vertical-align: top; width: 12%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#xa0;</td>
			<td style="vertical-align: top; width: 3%;">&#xa0;</td>
			<td style="vertical-align: bottom; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mark W. Reynolds</div>
			</td>
			<td style="vertical-align: top; width: 12%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#xa0;</td>
			<td style="vertical-align: top; width: 3%;">&#xa0;</td>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</div>
			</td>
			<td style="vertical-align: top; width: 12%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&#xa0;</td>
			<td style="vertical-align: top; width: 3%;">&#xa0;</td>
			<td style="vertical-align: top; width: 35%;">&#xa0;</td>
			<td style="vertical-align: top; width: 12%;">&#xa0;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center;">3</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_321172.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_321172.htm</title>

	<!-- Generated by ThunderDome Portal - 1/3/2022 9:24:38 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<div><img alt="logo.jpg" src="logo.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 18pt; font-variant: normal; margin: 0pt; text-align: center;"><b>GeoVax Issues Shareholder Update Letter</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>Letter from CEO Describes Achievements during 2021</i></b></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>and Sets Forth New Goals for 2022</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>ATLANTA, GA, January 4, 2022</b> &#8212; GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today issued an update letter from Chairman and CEO, David Dodd, to the Company&#8217;s shareholders and other interested parties. The letter is posted to the Company&#8217;s website and is appended in its entirety to the end of this press release.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About GeoVax</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer using novel proprietary platforms. GeoVax&#8217;s product pipeline includes two ongoing Phase 2 clinical trials of GEO-CM04S1 (formerly COH04S1) for COVID-19 as a universal booster vaccine to mRNA vaccines authorized by the U.S. Food and Drug Administration (FDA) and as a primary vaccine for use in immunocompromised patients. In addition to GEO-CM04S1 for COVID-19, GeoVax is developing GEO-CM02 as a pan-coronavirus vaccine. The Company is also conducting a Phase 1/2 clinical trial of Gedeptin&#174; for treatment of head and neck cancer. Gedeptin&#174; has been granted orphan drug status by the FDA. Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company&#8217;s portfolio of wholly owned, co-owned, and in-licensed intellectual property stands at over 70 granted or pending patent applications spread over 20 patent families.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For additional information about GeoVax, visit our website: www.geovax.com.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Forward-Looking Statements</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>This release contains forward-looking statements regarding GeoVax</i>&#8217;<i>s business plans. The words </i>&#8220;<i>believe,</i>&#8221;<i> </i>&#8220;<i>look forward to,</i>&#8221;<i> </i>&#8220;<i>may,</i>&#8221;<i> </i>&#8220;<i>estimate,</i>&#8221;<i> </i>&#8220;<i>continue,</i>&#8221;<i> </i>&#8220;<i>anticipate,</i>&#8221;<i> </i>&#8220;<i>intend,</i>&#8221;<i> </i>&#8220;<i>should,</i>&#8221;<i> </i>&#8220;<i>plan,</i>&#8221;<i> </i>&#8220;<i>could,</i>&#8221;<i> </i>&#8220;<i>target,</i>&#8221;<i> </i>&#8220;<i>potential,</i>&#8221;<i> </i>&#8220;<i>is likely,</i>&#8221;<i> </i>&#8220;<i>will,</i>&#8221;<i> </i>&#8220;<i>expect</i>&#8221;<i> and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to</i> <i>obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax</i>&#8217;<i>s immuno-oncology products and preventive vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax</i>&#8217;<i>s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventive vaccines with the desired characteristics in a timely manner, GeoVax</i>&#8217;<i>s immuno-oncology products and preventive vaccines will be safe for human use, GeoVax</i>&#8217;<i>s vaccines will effectively prevent targeted infections in humans, GeoVax</i>&#8217;<i>s immuno-oncology products and preventive vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax</i>&#8217;<i>s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. </i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Further information on our risk factors is contained in our registration statement on Form S-3 and the periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by U.S. federal securities law.</i>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contact:</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">investor@geovax.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">678-384-7220</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">###</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">January 4, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dear Fellow Shareholders:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">2021 has represented an outstanding year of progress for GeoVax. Thank you for your continued support of GeoVax, and sharing in our efforts to advance the application of our expertise, science, and technology towards improving the lives of millions worldwide.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Heading into 2021, we established and communicated the following goals:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2021 GOALS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>1.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Covid-19/SARS-CoV-2 Vaccine</b></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Achieve clinical development status within 12-18 months</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Immuno-oncology</b></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Achieve clinical development status within 12-18 months</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>3.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Hemorrhagic fever virus vaccines (Ebola, Lassa, Marburg, Sudan)</b></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Support National Institutes of Health (NIH) Preclinical Services and Department of Defense (DoD) activities related to animal testing evaluations of GeoVax vaccines</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>4.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Strengthen balance sheet</b>&nbsp;in support of achieving 2021 goals and beyond</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>5.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Strengthen resources and operations in support of our development goals</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In this message, I wish to highlight significant accomplishments achieved in support of our 2021 goals, while also outlining our goals and milestones set for 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2021 </b><b>ACHIEVEMENTS</b><b> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Goal Achievement #1</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Covid-19 vaccine: Advancing into Phase 2 Clinical Development and Potentially a Single-dose, Durable Coronavirus Vaccine</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As a result of the exclusive license of <b>GEO-CM04S1</b> (formerly COH04S1) executed with City of Hope, we have <b>two Phase 2 clinical trials underway</b> related to Covid-19:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Phase 2 trial among <b>immunocompromised patients</b>, directly comparing to the Pfizer/BioNTech mRNA vaccine;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This is the first trial to be conducted among a patient population with weakened immune systems as a result of cancer therapy. In this trial, we are conducting a direct comparison of GEO-CM04S1 to the Pfizer/BioNTech mRNA vaccine. We believe that our vaccine, eliciting both T-cell and antibody immunity, has the potential to provide better and more durable protection versus a vaccine that elicits primarily only antibody immunity. We also believe that the current vaccines, based on mRNA and adenovirus vaccine platforms, may be less effective and protective within immunocompromised populations. We believe that our approach of eliciting both T-cell and antibody immunity against multiple viral proteins may prove to be more potent and may provide better and more durable protection to such populations.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Phase 2 trial among healthy volunteers as a <b>booster</b>&nbsp;to individuals fully vaccinated with a mRNA vaccine (i.e., two-shot regimen);</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We also believe that GEO-CM04S1, which is designed to elicit both T-cell and antibody immunity, has the potential to provide broader protection and durability as a booster to mRNA vaccines versus simply providing a 3<sup style="vertical-align:top;line-height:120%;font-size:pt">rd</sup>&nbsp;or 4<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup>&nbsp;mRNA dose, which was designed primarily to induce neutralizing antibodies.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">###</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In general, we believe that <b>GEO-CM04S1</b> provides a differentiated opportunity as a <b>vaccine against variants</b> (i.e., Omicron) versus the concept of &#8220;chasing the variants.&#8221;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">GEO-CM04S1 is designed to elicit both T-cell and antibody immunity by incorporating a multi-antigen design targeting both the spike (S) and nucleocapsid (N) proteins of the SARS-CoV-2 virus. We believe that this multi-antigen approach may provide broader and more durable protection than a single-antigen vaccine design. <i>In simple terms, we believe our vaccine has a better chance of addressing the issues and dangers of evolving variants of concern, which we expect will continue to emerge.</i></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Further strengthening our Covid-19 vaccine portfolio is <b>GEO-CM02</b>, a potential <b>universal coronavirus vaccine that could be effective against multiple variants</b>, which is showing promise in animal testing.</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We designed GEO-CM02 to incorporate three critical proteins to support the in vivo formation of highly immunogenic VLPs (Virus-Like-Particles) intended to elicit both an antibody immune response targeting the S protein and a T-cell immune response targeting the membrane (M) and envelope (E)proteins. Promising animal results were reviewed during the 2021 World Vaccine &amp; Immunotherapy Conference, demonstrating protection with a single dose and protection against the Beta variant. Our focus with this program is towards a single-dose, durable universal coronavirus vaccine that could be effective against multiple variants and that can be distributed and administered without requiring extreme refrigeration or frozen state delivery.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Goal Achievement #2</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Immuno-oncology: Phase 2 Clinical Development of Gedeptin</b>&#174;<b> and Advancing MVA-VLP-MUC1 to IND-readiness</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our exclusive license of <b>Gedeptin</b>&#174; provides a Phase 2 stage therapy for advanced head and neck cancers. The U.S. Food and Drug Administration (FDA) granted orphan drug status to Gedeptin&#174; and we are currently expanding the number of trial sites in order to accelerate patient enrollment and validate the product for regulatory filing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We will also evaluate additional opportunities to expand the use of Gedeptin in conjunction with other cancer therapies, such as Immune Checkpoint Inhibitors (ICIs).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Separately, our <b>MVA-VLP-MUC1</b> immunotherapy is advancing towards IND-filing through critical animal efficacy testing models. The focus is on combining our vaccine and ICIs with the goal of enhancing the therapeutic performance and utility of ICI therapy. During the fourth quarter, we received a Notice of Allowance regarding our cancer (MUC1) vaccine patent, documenting the novelty of our vaccine approach.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Goal Achievement #3</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Hemorrhagic Fever Virus Vaccines: Ebola, Marburg, Lassa &amp; Sudan Advancing with NIH &amp; DoD Support</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Thanks to the continued support of NIH Preclinical Services and the DoD, our hemorrhagic fever virus vaccines continue to demonstrate promising immune responses and efficacy measures in animal testing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To date, we have demonstrated 100% protection with a single dose vaccine against Ebola in a lethal challenge non-human primate evaluation, and the data was recently presented at the 2021 World Vaccine &amp; Immunotherapy Congress. During the fourth quarter, we received a Notice of Allowance for our Ebola vaccine patent, which represents the basis of our technology related to hemorrhagic fever virus vaccines.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">###</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Goal Achievements #4 and #5</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Strong Balance Sheet </b>&#8211;<b> Enabling Transformative Business Developments into Phase 2 Status and Operational Strengthening</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We began 2021 with a clean balance sheet, having successfully listed on the Nasdaq market, and in early 2021, we further strengthened our balance sheet. As a result, we have added strength and depth in various operational areas that are critical for us to successfully proceed through clinical development and potentially into regulatory registration and/or business partnering/collaborations. During 2021, we also successfully completed transformative exclusive license agreements relating to Gedeptin&#174; and GEO-CM04S1 while also advancing our internal priority development programs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As we enter 2022, our focus will be on <b>the continuing progress</b> of our <b>three Phase 2 clinical programs</b> and ensuring that we have appropriate internal/external resources to support both our clinical programs and our IND-enabling initiatives in support of our priority internal programs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2022 </b><b>GOALS</b><b> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Goal #1</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Covid-19/SARS-CoV-2 </u></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Accelerate the two Phase 2 clinical trials to support the development of <b>GEO-CM04S1</b></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9632;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Immunocompromised patients</b>&nbsp;&#8211;&nbsp;direct comparison against the Pfizer/BioNTech mRNA vaccine</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9632;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Booster</b>&nbsp;among healthy individuals who previously received the two-shot regimen of an mRNA vaccine</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Advance GEO-CM02, our potential single dose, universal coronavirus vaccine through IND-enabling activities</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>While our priority will be on accelerating our GEO-CM04S1 clinical program, we remain encouraged regarding the potential of GEO-CM02. Our developments are well aligned with organizations such as NIH and the Coalition for Epidemic Preparedness Innovations (CEPI), which have established priority goals in supporting the development of universal coronavirus vaccines. We anticipate providing updates as results become available. We also recognize potential opportunities exist for collaborations as well as out-licensing of our programs, especially those advancing through clinical trials, which we will evaluate and consider.</i></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Goal #2</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Immuno-oncology</u></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Accelerate the expansion and enrollment of the <b>Gedeptin</b>&#174;&nbsp;clinical program within advanced Head &amp; Neck cancers</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Advance <b>MVA-VLP-MUC1</b>&nbsp;to through critical animal efficacy models to support IND-readiness</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Our priority is to expand and accelerate the Gedeptin</i>&#174;<i>&nbsp;clinical program. We anticipate providing updates throughout 2022 regarding the expansion and acceleration of the Gedeptin</i>&#174;<i>&nbsp;program, as well as updates regarding the progress of MVA-VLP-MUC1. We also recognize potential opportunities exist for collaborations and out-licensing of these programs which we will evaluate and consider.</i></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Goal #3</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Hemorrhagic Fever Virus Vaccines (Ebola, Lassa, Marburg, Sudan)</u></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We anticipate continued progress of these vaccines, working in conjunction with NIH and DoD, and we remain focused on the potential of clinical development support from such government entities.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Goal #4</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Resources and Capabilities</u></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">As we advance our portfolio, we will continue to strive to have appropriate organizational and operational resources to support advancing through clinical development into regulatory registration, including our abilities relative to collaboration and other corporate development activities. This will continue to be a critical area of focus and evaluation of internal and external opportunities.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">###</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>In addition to these goals, we will continue to enhance the communications activities via our website, press releases, social media, broadcast media, relevant conference participation and other venues. Our intent is to provide timely updates regarding our programs and progress, while also increasing the awareness of GeoVax to various constituencies (i.e., potential investors; potential collaborators; etc.). </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In summary, we appreciate your continued support. We are committed to accelerating the clinical development of GEO-CM04S1 and Gedeptin&#174;, advancing our other programs, ensuring resources and capabilities are in place to support increasing our contributions towards improved health worldwide, providing significant value to our shareholders, and promoting a highly motivating environment for high performance-oriented individuals to develop their careers. On behalf of all of us associated with GeoVax, we wish you a healthy, prosperous and wonderful 2022. Thank you.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Sincerely,</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">David A. Dodd</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chairman, CEO</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GeoVax Labs, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">###</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>govx-20220104.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 1/3/2022 9:42:17 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:govx="http://www.govx.com/20220104" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.govx.com/20220104">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="govx-20220104_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="govx-20220104_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="govx-20220104_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.govx.com/20220104/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="govx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="govx_CommonStockCustomMember" name="CommonStockCustomMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="govx_WarrantsToPurchaseCommonStockCustomMember" name="WarrantsToPurchaseCommonStockCustomMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>govx-20220104_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 1/3/2022 9:42:17 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.govx.com/20220104/role/statement-document-and-entity-information" xlink:href="govx-20220104.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.govx.com/20220104/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
<link:loc xlink:href="govx-20220104.xsd#govx_CommonStockCustomMember" xlink:label="govx_CommonStockCustomMember" xlink:type="locator"/>
<link:loc xlink:href="govx-20220104.xsd#govx_WarrantsToPurchaseCommonStockCustomMember" xlink:label="govx_WarrantsToPurchaseCommonStockCustomMember" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_CommonStockCustomMember" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_WarrantsToPurchaseCommonStockCustomMember" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>govx-20220104_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 1/3/2022 9:42:17 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
<link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
<link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>

<link:loc xlink:href="govx-20220104.xsd#govx_CommonStockCustomMember" xlink:label="govx_CommonStockCustomMember" xlink:type="locator"/>
<link:label xlink:label="govx_CommonStockCustomMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CommonStock Custom [Member]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CommonStockCustomMember" xlink:to="govx_CommonStockCustomMember-label" xlink:type="arc"/>

<link:loc xlink:href="govx-20220104.xsd#govx_WarrantsToPurchaseCommonStockCustomMember" xlink:label="govx_WarrantsToPurchaseCommonStockCustomMember" xlink:type="locator"/>
<link:label xlink:label="govx_WarrantsToPurchaseCommonStockCustomMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WarrantsToPurchaseCommonStock Custom [Member]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_WarrantsToPurchaseCommonStockCustomMember" xlink:to="govx_WarrantsToPurchaseCommonStockCustomMember-label" xlink:type="arc"/>


</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>govx-20220104_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 1/3/2022 9:42:17 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.govx.com/20220104/role/statement-document-and-entity-information" xlink:href="govx-20220104.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.govx.com/20220104/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
<link:loc xlink:href="govx-20220104.xsd#govx_CommonStockCustomMember" xlink:label="govx_CommonStockCustomMember" xlink:type="locator"/>
<link:loc xlink:href="govx-20220104.xsd#govx_WarrantsToPurchaseCommonStockCustomMember" xlink:label="govx_WarrantsToPurchaseCommonStockCustomMember" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_CommonStockCustomMember" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_WarrantsToPurchaseCommonStockCustomMember" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>

<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !) .X# 2(  A$! Q$!_\0
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M>7ZVL:_^U*H3_P#!5'P=']S0/$;_ %$*_P#L]5]1K_RLGZU2_F/J"BOE=O\
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M<S<7HRUA*=DFCX\/P._:2^&ISI'BY=<BCZ1F_$N1_NW"X_6HS^UQ\<OA./\
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JB@#'\.^ M*\*7336-KY4K1^5O:5Y"$SG:-Q.!GG ]JV***;;>X;;'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140028744485336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">GEOVAX LABS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Jan.  04,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-39563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">87-0455038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">1900 Lake Park Drive, Suite 380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Smyrna<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">GA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">30080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-7220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0000832489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_CommonStockCustomMember', window );">CommonStock Custom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GOVX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_WarrantsToPurchaseCommonStockCustomMember', window );">WarrantsToPurchaseCommonStock Custom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to Purchase Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GOVXW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_CommonStockCustomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_CommonStockCustomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_WarrantsToPurchaseCommonStockCustomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_WarrantsToPurchaseCommonStockCustomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>govx20220103_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:govx="http://www.govx.com/20220104"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="govx-20220104.xsd" xlink:type="simple"/>
    <context id="d20228K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2022-01-04</startDate>
            <endDate>2022-01-04</endDate>
        </period>
    </context>
    <context id="d20228K_StatementClassOfStockAxis_CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:CommonStockCustomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-04</startDate>
            <endDate>2022-01-04</endDate>
        </period>
    </context>
    <context id="d20228K_StatementClassOfStockAxis_WarrantsToPurchaseCommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:WarrantsToPurchaseCommonStockCustomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-04</startDate>
            <endDate>2022-01-04</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20228K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20228K">0000832489</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20228K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20228K">2022-01-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20228K">GEOVAX LABS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20228K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20228K">001-39563</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20228K">87-0455038</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20228K">1900 Lake Park Drive, Suite 380</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20228K">Smyrna</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20228K">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20228K">30080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20228K">678</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20228K">384-7220</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20228K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20228K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20228K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20228K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20228K_StatementClassOfStockAxis_CommonStock">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20228K_StatementClassOfStockAxis_CommonStock">GOVX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20228K_StatementClassOfStockAxis_CommonStock">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="d20228K_StatementClassOfStockAxis_WarrantsToPurchaseCommonStock">Warrants to Purchase Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20228K_StatementClassOfStockAxis_WarrantsToPurchaseCommonStock">GOVXW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20228K_StatementClassOfStockAxis_WarrantsToPurchaseCommonStock">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20228K">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$N"=M@;<)%PO[(#>@819VFQ;,;FI9,,5Z]AH:?04-^8!1"S*HW8;LT452HU
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M3U/G8#?&[FP],+MZI23F<U!RS[LP(_5VLVA[8=0JWZ"9*0,)F9\N.8,UV!:
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M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ U8DD5)>*NQS
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MK84: ]@W.9 $E^2J=51=Z7FFUS>36TGHX-R#8._AE8P=S8\?=_<#4$L#!!0
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ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( -6))%0'04UB@0   +$    0
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MXPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #5B214EXJ[',     3 @
M"P              @ &_#P  7W)E;',O+G)E;'-02P$"% ,4    " #5B214
M.JJBYT !   \ @  #P              @ &H$   >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ U8DD5"0>FZ*M    ^ $  !H              ( !%1(
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ U8DD5&60
M>9(9 0  SP,  !,              ( !^A(  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&      D "0 ^ @  1!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>118</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="govx20220103_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.govx.com/20220104/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="govx20220103_8k.htm">govx20220103_8k.htm</File>
    <File>ex_321172.htm</File>
    <File>govx-20220104.xsd</File>
    <File>govx-20220104_def.xml</File>
    <File>govx-20220104_lab.xml</File>
    <File>govx-20220104_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "govx20220103_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "govx-20220104_def.xml"
     ]
    },
    "inline": {
     "local": [
      "govx20220103_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "govx-20220104_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "govx-20220104_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "govx-20220104.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 30,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 118,
   "memberCustom": 2,
   "memberStandard": 0,
   "nsprefix": "govx",
   "nsuri": "http://www.govx.com/20220104",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx20220103_8k.htm",
      "contextRef": "d20228K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.govx.com/20220104/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx20220103_8k.htm",
      "contextRef": "d20228K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity, Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity, Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity, Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity, Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity, Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "govx_CommonStockCustomMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStock Custom [Member]"
       }
      }
     },
     "localname": "CommonStockCustomMember",
     "nsuri": "http://www.govx.com/20220104",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_WarrantsToPurchaseCommonStockCustomMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantsToPurchaseCommonStock Custom [Member]"
       }
      }
     },
     "localname": "WarrantsToPurchaseCommonStockCustomMember",
     "nsuri": "http://www.govx.com/20220104",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.govx.com/20220104/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001437749-22-000309-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-22-000309-xbrl.zip
M4$L#!!0    ( -6))%1/]@F9$1P  "RG   -    97A?,S(Q,3<R+FAT;>U=
M_W,3N9+_^>U?H0=U^TB5[9# >T"235U( N0>)!QAV:O[Y4J>D6UMQB/O:,;&
M^]??IUO2C,9Q$E@(),%;M45LS^A+J]7]Z59W:V=4CK/=G9&2Z>Y/?]LI=9FI
M7?7Q_QYM;FP\V>SAUYUU]^5/?\/O?^]VQ4N5JT*6*A7]N7@_JO)4%0=FK,1;
M4Y0R$UVQL?YH??/AYJ9XMK7Y>.O14_'VC>AV=W?&JI0B&<G"JO*7>U4YZ#Z]
MY[_-Y5C]<F]@BK$LNZDJ55)JD]\3B<E+E>/I4F5J,C*Y^B4W]W9_VEEW0][I
MFW0N;#G/^/6\[%K]I]H2&P\GY;;@+P9RK+/YEOCYC\J4V^_U6%EQK&;BG1G+
MW'VY+28R374^W!(/=2X>]C9TOBV2JK"FV!*R*LTV]3D)'8UE,=1YMV_*THSQ
MSN3CMBC5Q[(K,SW,MT2AAR-T[Q\KS82?P5QI0*W1AL']8V%<_^@(_J8CK"KT
MP$^EF1O:ZN\>?ASIOB[%LV>]C9WU_N[..CV%?R:[/WW&:#,UN.[!_ISW[62[
M/;Y43W=W]'@H9(;US<S0]'Z?#.\)6R311SQ-#\;SB<=R;BC;3=_, _QQ*@LM
M\W(K)_[*MMU4M^CG9FB3"_L0"WVTY_>T9K30B_#=>)(2.<LVQ1.PM"JV>1%?
M*O-!?A1'UE;HY!2[0XU,ACTE?IVDV&;BM2KQL%O?BP?Y+0BQ2(>HA\T+>HAF
M[2?=ZA/SW]&[;H9B4)BQV#\\$0?*)H7NHZ^]9*355(WQJA5I56"+"D@6<+O>
MO8HBUS5:F:?B5&$\+R#O1MS!2R,S"R8H:'";GS*X[[Q<%_40$>#WRI9Z,#]'
M@;WWK_>.W^]UQ$O\_U\RKV0Q%X\[?N;]7?'S_:>;&YO;PC/V:]F'8#C*DYYX
M<"QM*O_8$B]//OS/6D=(T=<&HGZ4&^SW.83]>")SB/.)2C1&\2<M-^1Q"A;(
MS(0^C2K,1$QEDN@<DZ.U2&2>@'OT>%SEIAQ!-TTTR:+2I'(N-.VK% ^*RFVG
M+&:VD=0%-4CM@/,ZXD!.=2H.3)I2 P+-B7TW*I[6DVTK;+-%W0"X4XP3S2I+
M>G$BBQ)#Z$$[UOUI*R:&?[V@V9GJ6XWQ48MX6$XF"IHUI?EK,!O841>JG(?7
M%74\P)_4,/JUHH"&E%;U[BC;]4U5>IZZHYOK_(8A/A!)IG.=R*QK2SE4%VR9
MR[?(PMX0<BAU;DOPUH"!5@7AJBUQ3VM+59;:RPV:!H^92:$!U;#;)YDL":J!
MP]V8:R;&4VF5E&*B)PK#5N@AR:H4S98S(TP^--3BVQ%Z$IOUS$0).D& @I]?
M'IYT]]\\?'RZ(1Y0%ZK(YF+_Y!5]L\82=O_DP]%!=^.9D$2<*M=3[$.TT3>T
MO8HP<=HGXW?'>Q$AJG)D"JP0 U?:0[_V3GN0XB;E21\4U5#LI6.,R98 N,"?
MXL&+@[TU_I5[ P7&1(#0!XVGLHKW*).8E@."!;0D*0 A +W5PUH*@I?<(H85
MS3&>4"=(3*QZM)S^Z4T_ IEW$U.8''*JP++YD3A1XT4*LTUF#8%G6@UJ17JB
M;ZPODIVIKE(UP7,_W]]X\GB;1U462I:D=^EWPMI,A5PE9YX[>HMOH7W15RH7
MPP),#P*88C(")Z9$5_!NB>%ZPH.J/9#:D01#@/Q2LDA&W(>?._<-8J*UL0U\
M1*)N2J)PJJ*%]=S\O_I,B@]$E@Y&/#9%,9)#G8@!7@%?T ]X^L%AWV2R(TZK
M5.8=\486_:H8=KCKU]):Z=8;&Y9V;X?(/E-91O\N;B.BT[C*2CW)E+ F@^8H
M*_1K6\O1; [@A0&>,D32&30(6-O,<@55DYBN_XNW:][-- "(9?$/RR?#+JVD
MVX2J*,G@P7.8.5:'YO;D841T08J#UAP,2#2$)D%KS,]07B @UI+?VGP8'F&9
M1AKK#DI5H+1Z]X&$$'EL9-)>E)%.Z8!!H'^%J8J@BK?$;#;K#969RH\][.R[
M2!T':4&CF2S2[FMCSHAS3K%;'>B^RUA6[[XG].1Q$[L:2)#0MF9J9)X:MJ8&
MGAWB%Q;+'HGH7;^_T1SD&ZE, F-0D;D7 S-38*N&)S<?TI-]:$=(I4[][09]
MN_ 0]1\& [UQ^<-C.;_\ 4!3**_RBCZ)"#JOKG@*5-:)GES9&@FO/+W\&3LR
M57;%,T3-J\9]92. +D-57M&1(7D(K7C%O*S(])G*KB#Y3&=7-*0^PM0I%QXA
M%6 UV%X6 @\0N"?9S:H(RF=.'$N6#* $J3I8(\(1VAD7.J4I#.:7\'%/_*:@
MKZ%$^Y*4#%JUZC*^SXAVI*YR%I!)512D-]SPO6JA84-!_>Y<=]9+UT%55A@@
M:VWWS$#G !":\8<B+5:.H,=F&(O;%%"]<R$'A$RYL^9YPC,LQSN$&*!X&3*2
M2G1#Z#3[CQ&< D!N]Y@KE6+V>TZ=AD:HPU2C1ZASO$6H"'-E"Q&0T=8HEHTQ
M1ZN(-FG%2R$%R1^RT#"F@4Q*X(".?Y.H.1LI0@Y;$<J3_8Q>I>476'C3)_DC
M &L J_BW,$ >2D#/T&>>J$OP,YF*.I_29A]*K_(\*+>="X26@S5=DR?.I@C/
M^Q4]#[@  .FAJ3E3#.> [V&;IC3<"9:!C&]ZU=&N;LT4[1;ZBK!S*A0O-3K
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M*GSZ=ZT*63</=.89G#F#/C;RY?1P'WHLOT3+@U5@,,/BAMU-[(V1VXF29S0
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M&-D/S3J/E@,;)V.=%"9?"R*;C063<VX/H+C/W$Z@+4+ ;6BE%S*X;Y;_: 5
MOA( B:SHOP@R*!-,YXDIP)K2&^QLIW5]7K)OU2?=U@8?<9F=Z#,@XE-7G":O
MDDR91$ZL3L6#X[7&OO-NW"CBDRW8\T:F.W5J]5[;G"TCT$.?2ZU 2G*5PCIO
M>F@N;#<WJ1YEN&-W,P;"&!1;T=$6C[P,#,9DL#^QV>ALF4Z0TY2+(?B=IUW)
M1$9B,A^2_4'6,LP1/F4.&]/E\9(K):]QC/*E"UQF90CCY\7D=,5>G09[0T'+
M=13*\>FPMC[,#6>$B\<N424C,%$CEC>=1U5&(!H_-B6ZEA2NBA-*^W$F]7E'
M1B2M([0/RY#C^+UKA?/K6Q$HO95 OIL"^3?52.&Z2!J;(D'$$G<5"@J<TFV3
MV W&?BMW6,Z2!-)*3XV(\L '[OS=2V\#@:83\>'U6RL><(FQ[FL(Y.Y;JO0(
M66S76B588HW U25C3="4IH@$/0OM,#ZG/H(NN?REL1KW"TG>DC=.-ZB<3SSQ
MQ>%:F&]/O.7MX:PRWATA67M&A0\*-=5JIM)08I4:YC/SWRAW*)R"BI_E>+(M
MCJ(J:'/(AIQQ%R4HI6J,$99>N44*PGMWG()@B[+E*>6Z!6Z[4\_/J2"TYXB>
M.*$2,":IZMH:7/"2R\*Q+]YG0=7JQ]FK04M]9>'CD_KI+5?!I"Z^X#.-I*\?
MJ KOU*(:."X5G*/A/D*XCHG@ ]A8/C:&*[H4YD_E*PF CI3%5<QOM-E\7?$*
MFS<E7N$Z9=?YF/VMRV,7HB*-[%3EDHL4ND),UP1!O/FPUX60ZK[Y=9\/>XZ.
M#[H%I\@!-]T$HEX#;CGA=,D+PA;.T2RV&0/%76'5(-$&7#"0LS/3I94O?5VW
M3ZT>>DDY3"H&VBZBR=4^_,&>.Z.""@)6]0FJ)![S:MQ7G*;JG/%4JI##ZQC:
M< AN L7!-?KK(TB5%R;+ZC"8*>B9.@59%[;AB4?%=P8ZB^#37>*8WY3#_>Q0
M]@'**BX2V7@/M*L?Y5: J54YY@KK1H2'_?![E4>JSE7=:9W?<DEJ/BN#;7/D
M5/K^"$PU,4 .XBCG4OY4;.7!T?Z17;N+=#^E8'(NU]5ANP(;-!98[(?1+71!
M1=)JX194/0DUQYR$[TPU'#4(SZ,;J')\3.9U&/K80*GZC>O0A.9"/(D9]YM@
MR-I#A+6F56C*[5"8)%N7^2B,9A1$AJK0-Y7Y8?A(MBJ]CR\S'P2%III3_(,&
M8@T,F5SBCPHHDNJ S50H@D7P[]B@6>:U/4I6YH:;^I.<?NX8[ $1;ZTQSKBF
M*R 0IDD;OI8;5,?9#:@U5V_UWT:&^R1 \>@' 11QFM +3A/Z$,<PVBWATX3J
M_"#.%_*HGG.%(B3!G']\],K_?& .A$\HN0FDO ;AQ.4=;(B065K9@<AQ8:8,
MO04J.<EV0?GIJ !BY')JS";EW1@<S[I8QI"-NR#7QDK:JG!Z?[F_XTZMC>$B
M94T@:42RE ];KK V%UW_O!-<+<9,P9[+R,N892H?DIS,NZYR(I]PEBK*8>K4
M2XWQ2#X/)8G-*"VJ*E)^I@7-Q4:^4#40>B/6<U-;5 ;.7U:7/G$'&WUIM0WZ
M(*HL$H7>7L7(7[OPUI?7"EP=YZZ.<U?'N=_H./<3 )@5]Q^SU+S_SQ\$B)V6
M!87'/?=)D:>4%"F<!^+IYL8&NVT.<RI0A*?>%S*WWN\,Q?8\%+ ^B$M-MG);
M3IWO@$AZ$M+K"(S$QS8W@<K78[CW80'E3K5Z/9]D2BZDH%(X%Y\!PN"FNL$N
MW##3?/\2'U@JX>ZB\K6#P[T;0DE*:JD+20W.G8E1 ]"6K>YZ(LJD:4"*3.DX
M(+SJ[S:9X"\Z;L#$Z=H=$ZV@+)3T%5;9_Q-LVJ8@:FLZ0#R)XGI6W@9>5A&"
MW>Q1SA-S4N3D:=6QQ</KZ*NYQ #@(U>$2=8A13/9-T6(63YH[F)SD>CD2FD-
M+Q1:Q@#;+'[>5]<4+7;0P^=@+'&-18?P449CXR*@I>&+N%S=<VT*,L&7W2AS
M%V'RGN63;2X;3:F;SA8)AR>NN#26F;*P&A/'']4P!&4/C,>#_!2=GIW+U@HD
MY*?=D9,-R#4J7\R.!:P!(>BP)NN8@5N<)D\X.HOC S/V;"SVY;*)\0LY?U00
MGIH\=,Q5R_*+Z_6/..+V+OZ2G-;-D-/:E'V[>\FL=RJ!%9-:5I5M88:K4(4[
M%JJPUQS(L-OXDAS8A<B$A?L(SH5 WKI4B&LL[/-U<G(>;=Z6G)SZ$/FBY%9'
M9&]UN _G$P3CR(O+\@)7G/9#<]KSQ8RN=@Y8G-PU&_'5#5,R<+)YX[?THJ^5
MS,5AG?GM9K25@OQR!>FK88<X/F>Y-&&DD2^_<V5,ES.'6X9"4ZILQ5T_'G?M
MZ-W?V%O0L@HCB[@.F D^A,C/L&B*^K.8,5W5IO($3\LAWWT63N;;681-_OVF
MBV5LW2%#?AYWNVSF EE=^$@QE+G^,US9ZH-&Z/0QG#[MPS)R]PF3<^APHE,U
MU@D=3D*MJY2]-T=Y;J:^C0?[AV^/UL(Q$)OG<8WTFB:N&E1C2H?Y+,#02W>@
M2S:0]1614;ZCNY2'TX1#_&E? 8O@\:G4&>V[)FD?>L,,0886-5N!.>JCMBYL
MJ>V>BN_L-57I+]/EM0V> ><'Z( *[JYYRF+DZ^JB<)-%OYI#Z%$.@;LUK8X?
MXD+SZ =BXR[F#UQHH-^8B,VO,ZESQ917MOE=5@X+MCE'^MF0X1V%3?K,JJ5!
MI8[^BYHBE/^H@TGIL@H? G <A9.N(,D/R'4>\"X)@:P+9EP9W.B"&F.7T4*\
M]XJO?C2^ M0]:1U]Q.'+_'];W#6R3(>D@G =X:(XNQK6>8:EE!<^G6ACXK9D
M;2"WR[:Z8C U^(Z@7>AV 7J'NYO0:+RUO@ZPY%.H!43I;H2N3ZI6\+ -#V],
M_.W7F=158;975N-?P<F[+(#;,K()(X[%DA,83>VYF2G._"UQYU))@M7/H<4^
M.\A['_A@OPEH:?D<EE\/XE$"W\7+;H4A70B=CUV&4,G"[T=).KS_^&[)I7>M
MPNO[<N)*4['+<R5R[K+(<6$_X4))YSCW]1DZ-0Z)$PXH9=E5@#P7J!.['F76
MKN%_4=3.)2ZS6/I<%GK6H:S]K*HSFVK>]0%A;K0M,!9=;]_D^[="WVJ?/Z5]
M:7N>#GU%X8.U=07#B42GBY=BZ[^.^Z?OZR@B_BG$,;6 XXV6G:O ^%5@_"HP
M_H;4.7/%D$+*L<\ZLZJ^KF.)U':II\JGIX4+;9U9VMS$--62)>A,]2DQO,-I
M22Q&E;1,)4/G'6*L4@WKA,L[)9)J7;@OZ,$I7322U(4]. [8(=JVW)TJ#,VZ
M8RTN?U)Z?T,H'E6"<-E\B:$>'\*$4B ,CULWE4 G4$ATL.SE#"(Z]QC:7R2%
MSD(H-1G7=+\5ADR$\ 7=&E2L\RG=;U)@]S1?-BJ%?U!ETEOKB=H\OUVH\!.*
MZ]EJC*_F+F8;>I\.OZ WE]]F[5PFA6,W788+ON+#4F;&9=J^77><8[=;X=R=
MA:AMQU'1P5R(*6Y?*)1$N):'!CMHDLE$Q8 DXILP+Z[1PGNE?6VV*_% %Z'5
MUV1W(L]6?/,.@0'NAMJTT6WIG<#!8^.KNOG20?1YZNBD\JDNC+.TR*]$3\0I
MXUU3:)<\&$?2<'(HTY0(K2GCNU!<@.*$JL^,9#;@ )J,;3Y"+9:W=UU1.=Q%
MSO+$COCV<AF"=GBB%H,P'N_,#%W ,:@R=_%/<^/Y;8R7OK(8@:;#%ZI%< <G
M=R#!0F*O)PY,FG[COO='4A-3=\3^X<DW[MMKA=>RCUUYE"??G7'O).C^QL#^
M]=[I^VX#A9="]:\*P0,"Q1]4M@U08%2.L]W_!U!+ P04    " #5B214H21O
M'*L#  #<#P  $0   &=O=G@M,C R,C Q,#0N>'-DS5??;]LV$'X?L/^!T[M,
MRVDW6(A3%,E6&$BZH$FQO14T=;:)2J3&'XWSW^](B;:5R(GL#L6>1)'?Q_ON
M>#R=SM]MJI)\ VV$DK,D&XT3 I*K0LC5+/E\E[Z_NYS/$V(LDP4KE819(E7R
M[N+GG\Y_2=,/($$S"P59/)+[M9,%Z"M5 ;E5VK*2I"2C9W0RGDS(-'\SR;/?
MR.U-FGKVQA2YX6NH&$$)TN2;A2[%+%E;6^>4/CP\C/S,2.D5;C ^HT)Z$1R2
MB#=%!_UP%K$9_?OF^B[LO0670G[M@V?3Z92&U0B52DI7]0LIK*;VL0:*H!11
MH 6//&-KO64%A@$^6JEOU*_X(&01^DQ,UU._O&!FZ^D .5TI'E#8KIAV][>T
M68S0 D2_:%SH:.;*2:L?^\'M8H=@!#\0#L&[.SNM,><.;=VN=BBPX>M^N%_I
M0'%RTXF>GQAQ586T'&?C-PEAUFJQ<!;^4+JZ@B5S)4;/R7\<*\520(&7HH0*
MI.T ]I8MTRNP'UD%IF8<7C$8\U]4-=X3(GMIA[*_N337BC,;[NQ!BG]+(R_U
M4VDV2<^R$9I.Z-$:IE2K$E,-5O["#]-1:MUA>153KR+[]105_==OB)!]YL>&
M>+R60Y>Z3X YB ^CU(^^+P2GN?]=OC^K(0-S,1*\V;>G!'M7C ;%.L+]X)A(
MOU#3!MG=I\27D^WORN2P_&KA?G"ZS]UB.\SI?<[V[60)>P5\D/DM/HRZ9EO#
M3$IEPQY1"JMK(9?*O_J/;1Z_N)]@24(SD#/-?>%ZN66@M58U:"O ['^TPP9K
M#<M9XFM_&NO^EY(M1OA5BI!G!KKU.Q1.I$!YO9,7N?XVSQ*#,2VA"?&/=*2
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MD];<JUNG^1H3_!77CB'\0&?I[J<:7_\%4$L#!!0    ( -6))%2-+/VD>04
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M-I<_'GN'EL!4^A&._0W&1X0HPFD/,PX3(]&M^?3XUWKD#WM/RM5<>8' \9R
MZ[^74L1BA*D70SP&?B*YS#[.3!/'0/4B\=:#G<K4T,UYR<Y4;SQ,QN#MQCN1
M;TY/I=D7)B@A\OT&?MN/@>Z6ZZ]$]4A3]K*\"%F<!K!&T+CR4ZIJX4M0HT@U
MAV&27JC@Z*EO+%<J,$P8C],X\%:"[LW;]I1R/;HC@P:E%%.L@7WU<X/55$M1
MLR8!2PDJVN^%),+"@RD3VRD7$&H"?@18CQ_H"VV,8#UI@)_NT@%OWZP*@L9
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M75A03?@I'CF M&Z4[:!UDT%[;M&IJ[),H6SF?3. E.'HGW!>./TI"C[%,SE
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M8NCQ/L)3A4.4QVMZ(H=AV@5;,B38K!9=K164BF"P(>AQ0HJC/A]0+O\B^B9
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M,3 T+GAS9%!+ 0(4 Q0    ( -6))%2-+/VD>04  *<T   5
M  "  18@  !G;W9X+3(P,C(P,3 T7V1E9BYX;6Q02P$"% ,4    " #5B214
MMRZLE+\&   ?10  %0              @ '")0  9V]V>"TR,#(R,#$P-%]L
M86(N>&UL4$L! A0#%     @ U8DD5!?E&*((!0  @#0  !4
M ( !M"P  &=O=G@M,C R,C Q,#1?<')E+GAM;%!+ 0(4 Q0    ( -6))%28
M[0KPH1$  $]R   3              "  >\Q  !G;W9X,C R,C Q,#-?.&LN
9:'1M4$L%!@     &  8 A $  ,%#      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
